$ACET
Adicet Bio, Inc.

2020 Q3 Form 10-Q Financial Statement

#000156459020051476 Filed on November 05, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2019 Q3 2019 Q2
Revenue $3.030M -$7.050M $6.070M
YoY Change -142.98%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.740M $1.850M $1.380M
YoY Change 318.38% -18.5% -39.21%
% of Gross Profit
Research & Development $8.942M $6.331M $16.55M
YoY Change 41.24% -6.42% 39.75%
% of Gross Profit
Depreciation & Amortization $840.0K $30.00K $30.00K
YoY Change 2700.0% 25.0% 50.0%
% of Gross Profit
Operating Expenses $16.68M $8.178M $19.17M
YoY Change 104.0% -9.46% 35.83%
Operating Profit -$13.66M -$15.23M -$19.17M
YoY Change -10.31% 68.57% 35.83%
Interest Expense $50.00K $280.0K
YoY Change -82.14%
% of Operating Profit
Other Income/Expense, Net -$1.224M $171.0K $847.0K
YoY Change -815.79% -72.64% 62.26%
Pretax Income -$14.78M -$14.78M -$18.32M
YoY Change -0.01% 75.78% 34.81%
Income Tax $3.000K $12.00K $10.00K
% Of Pretax Income
Net Earnings -$14.78M -$14.78M -$2.651M
YoY Change 0.01% 75.78% -80.49%
Net Earnings / Revenue -487.76% -43.67%
Basic Earnings Per Share
Diluted Earnings Per Share -$2.837M -$6.874M $26.81M
COMMON SHARES
Basic Shares Outstanding 36.22M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q3 2019 Q3 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $108.1M $117.3M $132.8M
YoY Change -7.83% 1.65% 5.48%
Cash & Equivalents $84.96M $23.00M $21.37M
Short-Term Investments $23.16M $93.60M $111.4M
Other Short-Term Assets $55.00K $21.00K $22.00K
YoY Change 161.9% -12.5% -99.12%
Inventory
Prepaid Expenses $2.416M $3.998M $3.270M
Receivables
Other Receivables
Total Short-Term Assets $117.4M $121.3M $136.1M
YoY Change -3.19% 3.64% 5.99%
LONG-TERM ASSETS
Property, Plant & Equipment $2.043M $437.0K $325.0K
YoY Change 367.51% 36.99% 8.33%
Goodwill $20.74M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.187M $200.0K $200.0K
YoY Change 993.5% 100.0% 100.0%
Total Long-Term Assets $32.99M $682.0K $570.0K
YoY Change 4737.1% 69.23% 42.5%
TOTAL ASSETS
Total Short-Term Assets $117.4M $121.3M $136.1M
Total Long-Term Assets $32.99M $682.0K $570.0K
Total Assets $150.4M $122.0M $136.7M
YoY Change 23.32% 3.86% 6.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.800M $9.973M $8.242M
YoY Change -61.9% 137.4% 83.16%
Accrued Expenses $6.800M $2.220M $1.464M
YoY Change 206.31% -33.99% -77.82%
Deferred Revenue $19.39M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $30.08M $12.19M $9.706M
YoY Change 146.67% 51.2% -16.33%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $41.00K $6.000K $11.00K
YoY Change 583.33% -72.73% -56.0%
Total Long-Term Liabilities $41.00K $6.000K $11.00K
YoY Change 583.33% -72.73% -56.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $30.08M $12.19M $9.706M
Total Long-Term Liabilities $41.00K $6.000K $11.00K
Total Liabilities $33.47M $12.20M $9.717M
YoY Change 174.34% 50.87% -16.23%
SHAREHOLDERS EQUITY
Retained Earnings -$97.37M -$125.2M -$100.8M
YoY Change -22.26% 90.81%
Common Stock $214.2M $234.9M $227.6M
YoY Change -8.81% 7829800.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $116.9M -$54.13M -$39.75M
YoY Change
Total Liabilities & Shareholders Equity $150.4M $122.0M $136.7M
YoY Change 23.31% 3.86% 6.12%

Cashflow Statement

Concept 2020 Q3 2019 Q3 2019 Q2
OPERATING ACTIVITIES
Net Income -$14.78M -$14.78M -$2.651M
YoY Change 0.01% 75.78% -80.49%
Depreciation, Depletion And Amortization $840.0K $30.00K $30.00K
YoY Change 2700.0% 25.0% 50.0%
Cash From Operating Activities -$7.830M -$21.65M -$14.34M
YoY Change -63.83% 101.96% 46.48%
INVESTING ACTIVITIES
Capital Expenditures -$630.0K -$190.0K -$30.00K
YoY Change 231.58% 533.33% 50.0%
Acquisitions
YoY Change
Other Investing Activities $45.90M $18.00M $25.00M
YoY Change 155.0% -201.41% -133.54%
Cash From Investing Activities $45.27M $17.81M $24.98M
YoY Change 154.18% -200.17% -133.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 40.00K 6.090M 3.550M
YoY Change -99.34%
NET CHANGE
Cash From Operating Activities -7.830M -21.65M -14.34M
Cash From Investing Activities 45.27M 17.81M 24.98M
Cash From Financing Activities 40.00K 6.090M 3.550M
Net Change In Cash 37.48M 2.250M 14.19M
YoY Change 1565.78% -107.89% -116.82%
FREE CASH FLOW
Cash From Operating Activities -$7.830M -$21.65M -$14.34M
Capital Expenditures -$630.0K -$190.0K -$30.00K
Free Cash Flow -$7.200M -$21.46M -$14.31M
YoY Change -66.45% 100.75% 46.47%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2014-11-30
acet Number Of Warrants Exercised
NumberOfWarrantsExercised
0
CY2019 acet Warrants Outstanding And Exercisable Weighted Average Remaining Contractual Term
WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm
P6Y7M20D
acet Warrants Outstanding And Exercisable Weighted Average Remaining Contractual Term
WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm
P5Y11M8D
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
23160000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1786000
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020Q3 us-gaap Assets Current
AssetsCurrent
117411000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
51793000
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9291000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2043000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2121000
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
us-gaap Operating Expenses
OperatingExpenses
42335000
CY2020Q3 us-gaap Goodwill
Goodwill
20739000
CY2020Q3 us-gaap Development In Process
DevelopmentInProcess
3490000
CY2020Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
4527000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
10588000
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2187000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
410000
CY2020Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
19390000
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
10993000
CY2020Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
6849000
CY2019Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
2820000
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
30077000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14865000
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
10890000
CY2020Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
102000
CY2019Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
234000
CY2019Q4 acet Redeemable Convertible Preferred Stock Warrant Liability
RedeemableConvertiblePreferredStockWarrantLiability
1881000
CY2020Q3 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
2880000
CY2020Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
367000
CY2020Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
41000
CY2020Q3 us-gaap Liabilities
Liabilities
33467000
CY2019Q4 us-gaap Liabilities
Liabilities
27870000
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
140200938
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2155578
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2155578
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
1000
CY2020Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
214213000
us-gaap Operating Income Loss
OperatingIncomeLoss
-24211000
CY2020Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
153000
CY2019Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
276000
us-gaap Interest And Other Income
InterestAndOtherIncome
704000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1224000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
9258000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-97367000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-69647000
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
83000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
23000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
116930000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-60366000
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
150397000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
81587000
CY2020Q3 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
3028000
CY2019Q3 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
-7047000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
12493000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
-974000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8942000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6331000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24651000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17168000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7741000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1847000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17684000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6069000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
16683000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
8178000
us-gaap Operating Expenses
OperatingExpenses
23237000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13655000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-15225000
us-gaap Operating Income Loss
OperatingIncomeLoss
-29842000
us-gaap Interest And Other Income
InterestAndOtherIncome
561000
CY2020Q3 us-gaap Interest Expense
InterestExpense
50000
us-gaap Interest Expense
InterestExpense
84000
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
171000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1174000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2091000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14776000
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14778000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-30396000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21559000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2676000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-14779000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-14778000
us-gaap Net Income Loss
NetIncomeLoss
-27720000
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.84
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-6.87
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-8.69
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-10.10
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5208887
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2149986
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3190557
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2133645
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-114000
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-5000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
60000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
11000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14893000
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14783000
CY2020Q3 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-114000
CY2019Q3 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-5000
us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
60000
us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
11000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-27660000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21549000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-60366000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
42000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
299000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-4486000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-15000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-64526000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
351000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-8455000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
189000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
144000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2966000
CY2020Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
114083000
CY2020Q3 acet Stock Exchanged During Period Value In Connection With Merger
StockExchangedDuringPeriodValueInConnectionWithMerger
84142000
CY2020Q3 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
2922000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-14779000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-114000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
116930000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-33516000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-4131000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9000
CY2019Q1 acet Stock Issued During Period Value Vesting Of Early Stock Options Exercised
StockIssuedDuringPeriodValueVestingOfEarlyStockOptionsExercised
47000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
251000
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
18000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-2651000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
223000
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-39745000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-14778000
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
8000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
391000
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-5000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
-54129000
us-gaap Profit Loss
ProfitLoss
-27720000
us-gaap Profit Loss
ProfitLoss
-21560000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
911000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
962000
us-gaap Share Based Compensation
ShareBasedCompensation
3616000
us-gaap Share Based Compensation
ShareBasedCompensation
865000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-3000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
4000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
143000
acet Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liability And Trdf Liability
ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFLiability
2024000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
897000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-62000
acet Amortization Of Debt Issuance Costs
AmortizationOfDebtIssuanceCosts
84000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5000000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-837000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
1560000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-19000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1442000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
244000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-2493000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
974000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-119000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-111000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1738000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-627000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
1000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28207000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20623000
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
64114000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
5700000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
60056000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
44985000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
17750000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
630000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
611000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
102769000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-42917000
us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
77044000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
193000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
24000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
157000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
36000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
77068000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
74598000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
13528000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14889000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13757000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
89487000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27285000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
84960000
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23003000
CY2020Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
4527000
CY2019Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
4282000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
89487000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27285000
us-gaap Income Taxes Paid
IncomeTaxesPaid
3000
us-gaap Income Taxes Paid
IncomeTaxesPaid
1000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
76000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
58000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
114083000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
2922000
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
84142000
acet Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
47000
acet Issuance Of Redeemable Convertible Preferred Stock On Exercise Of Warrants With Loan Agreement
IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement
144000
acet Termination Of Redeemable Convertible Preferred Stock Tranche Liability
TerminationOfRedeemableConvertiblePreferredStockTrancheLiability
1143000
acet Settlement Of Trdf Liability
SettlementOfTRDFLiability
88000
acet Entity Date Of Merger
EntityDateOfMerger
2020-04-28
CY2020Q3 us-gaap Equity Method Investment Ownership Percentage
EquityMethodInvestmentOwnershipPercentage
0.25
CY2020Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-7
CY2020Q3 acet Exchange Ratio
ExchangeRatio
0.1240
CY2020Q3 us-gaap Equity Method Investment Ownership Percentage
EquityMethodInvestmentOwnershipPercentage
0.25
CY2020Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-7
CY2020Q3 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
0
CY2020Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1240
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates<span style="font-weight:normal;font-style:normal;"> </span></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:7.14%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements as well as the reported amounts of revenues and expenses during the reporting period. Such estimates include the valuation of the intangible assets acquired in business combinations, redeemable convertible preferred stock warrant liability, redeemable convertible preferred stock tranche liability, the Technion Research and Development Foundation liability (“TRDF Liability”), contingent consideration liability for contingent value right (“CVR”), deferred tax assets, useful lives of property and equipment, accruals for research and development activities, revenue recognition and stock-based compensation. Actual results could differ from those estimates. The current COVID-19 (coronavirus) pandemic, which is impacting worldwide economic activity, poses risk that the Company or its employees, contractors, suppliers, and other partners may be prevented from conducting business activities for an indefinite period of time, including due to shutdowns that may be requested or mandated by governmental authorities. The extent to which the coronavirus impacts the Company’s operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the outbreak, new information that will emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others. COVID-19 may impact the timing of regulatory approval of the INDs for clinical trials, the enrollment of any clinical trials that are approved, the availability of clinical trial materials and regulatory approval and commercialization of our products. COVID-19 may also impact the Company’s ability to access capital, which could negatively impact short-term and long-term liquidity.<span style="font-size:12pt;"> </span></p>
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2020Q3 us-gaap Business Combination Step Acquisition Equity Interest In Acquiree Percentage
BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage
0.750
CY2020Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-7
CY2020Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
23077000
CY2020Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
83000
CY2020Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
23160000
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
62358000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
7000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
30000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
62381000
CY2020Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
23160000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
51793000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
10588000
CY2020Q3 us-gaap Marketable Securities
MarketableSecurities
23160000
CY2019Q4 us-gaap Marketable Securities
MarketableSecurities
62381000
CY2020Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2416000
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
615000
CY2020Q3 us-gaap Prepaid Insurance
PrepaidInsurance
3353000
CY2019Q4 us-gaap Prepaid Insurance
PrepaidInsurance
57000
CY2020Q3 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
3400000
CY2019Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
722000
CY2020Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
67000
CY2019Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
213000
CY2020Q3 us-gaap Other Assets Current
OtherAssetsCurrent
55000
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
179000
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9291000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1786000
CY2020Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6592000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5759000
CY2020Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4549000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3638000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2043000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2121000
CY2020Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
300000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
900000
CY2019Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
300000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1000000.0
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4455000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1359000
CY2020Q3 acet Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
552000
CY2019Q4 acet Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
450000
CY2020Q3 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
1016000
CY2019Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
301000
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
826000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
710000
CY2020Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
6849000
CY2019Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
2820000
us-gaap Debt Instrument Maturity Date Range End1
DebtInstrumentMaturityDateRangeEnd1
2021-10-28
CY2020Q3 acet Loan Amount Drawn
LoanAmountDrawn
0
CY2020Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
100000
acet Incremental Expense
IncrementalExpense
0
CY2020Q3 us-gaap Deferred Finance Costs Gross
DeferredFinanceCostsGross
200000
CY2020Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
200000
us-gaap Operating Lease Payments
OperatingLeasePayments
600000
CY2019Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
200000
us-gaap Operating Lease Payments
OperatingLeasePayments
500000
CY2020Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
1018000
CY2020Q3 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
4124000
CY2020Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
3560000
CY2020Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
3428000
CY2020Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
3525000
CY2020Q3 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
17371000
CY2020Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
33026000
acet Lawsuits Filed Against Company
LawsuitsFiledAgainstCompany
5
us-gaap Litigation Settlement Expense
LitigationSettlementExpense
200000
CY2019Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
99363444
CY2019Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
114083000
CY2019Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
128195000
CY2019Q4 acet Temporary Equity Shares Issued And Outstanding
TemporaryEquitySharesIssuedAndOutstanding
97166921
CY2019Q4 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
12048671
CY2020Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
2900000
CY2019Q4 acet Class Of Warrant Outstanding And Exercisable To Purchase Preferred Shares
ClassOfWarrantOutstandingAndExercisableToPurchasePreferredShares
1781387
CY2019Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.4034
acet Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
128260
acet Number Of Securities Converted To Warrants To Purchase Common Stock
NumberOfSecuritiesConvertedToWarrantsToPurchaseCommonStock
-1672854
CY2020Q3 acet Class Of Warrant Outstanding And Exercisable To Purchase Common Stock
ClassOfWarrantOutstandingAndExercisableToPurchaseCommonStock
236793
CY2020Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
11.3177
CY2020Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
236793
CY2020Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
5593764
CY2019Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
14834849
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2966000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
391000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3616000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
865000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
195898
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
16.11
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14779000
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14778000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-27720000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-21560000
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5208887
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2149986
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3190557
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2133645
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.84
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-6.87
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-8.69
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-10.10
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3495590
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13589161

Files In Submission

Name View Source Status
0001564590-20-051476-index-headers.html Edgar Link pending
0001564590-20-051476-index.html Edgar Link pending
0001564590-20-051476.txt Edgar Link pending
0001564590-20-051476-xbrl.zip Edgar Link pending
acet-10q_20200930.htm Edgar Link pending
acet-10q_20200930_htm.xml Edgar Link completed
acet-20200930.xsd Edgar Link pending
acet-20200930_cal.xml Edgar Link unprocessable
acet-20200930_def.xml Edgar Link unprocessable
acet-20200930_lab.xml Edgar Link unprocessable
acet-20200930_pre.xml Edgar Link unprocessable
acet-ex311_9.htm Edgar Link pending
acet-ex312_6.htm Edgar Link pending
acet-ex321_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending